Jiangsu Yahong Meditech Co Ltd
Shanghai Stock ExchangeTotal Valuation
Jiangsu Yahong Meditech Co Ltd carries a market capitalization of 7.50B, placing it among publicly traded companies globally. Its enterprise value stands at 3.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.50B |
| Enterprise Value | 3.61B |
Share Statistics
Jiangsu Yahong Meditech Co Ltd currently has 570.00M shares outstanding.
| Shares Outstanding | 570.00M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 19.66, and the price-to-book ratio stands at -4.84.
| PE Ratio | N/A |
| PS Ratio | 19.66 |
| PB Ratio | -4.84 |
| P/TBV Ratio | 2.80 |
| P/FCF Ratio | 429.86 |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 14.37 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 166.41 |
Financial Position
Jiangsu Yahong Meditech Co Ltd maintains a current ratio of 5.93, meaning it holds 5.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.17, indicating elevated leverage, while an interest coverage ratio of -41.12 demonstrates limited ability to service its debt obligations.
| Current Ratio | 5.93 |
| Quick Ratio | 5.05 |
| Debt / Equity | 14.17 |
| Debt / EBITDA | -0.66 |
| Interest Coverage | -41.12 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -15.69 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 11.52 |
Taxes
| Income Tax | -941,559.63 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Jiangsu Yahong Meditech Co Ltd's stock has gained approximately 40.10695% over the past 52 weeks. The 50-day moving average sits at 11.45, while the 200-day moving average is 11.77.
| Beta (5Y) | N/A |
| 52-Week Price Change | 40.10695% |
| 50-Day Moving Average | 11.45 |
| 200-Day Moving Average | 11.77 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Jiangsu Yahong Meditech Co Ltd generated 251.31M in revenue and converted that into -362.29M in net income, yielding earnings per share of -0.62. EBITDA reached -387.34M, while operating income came in at -387.34M.
| Revenue | 251.31M |
| Gross Profit | 184.32M |
| Operating Income | -387.34M |
| Pretax Income | -372.63M |
| Net Income | -362.29M |
| EBITDA | -387.34M |
| EBIT | -387.34M |
| Earnings Per Share (EPS) | -0.62 |
Balance Sheet
Jiangsu Yahong Meditech Co Ltd holds 1.58B in cash and equivalents against 257.13M in total debt, resulting in a net debt position of -513.49M. Total book value stands at -1.02B, with working capital of 1.54B providing operational flexibility.
| Cash & Cash Equivalents | 1.58B |
| Total Debt | 257.13M |
| Net Debt | -513.49M |
| Equity (Book Value) | -1.02B |
| Book Value Per Share | -1.83 |
| Working Capital | 1.54B |
Cash Flow
After subtracting -12.31M in capital expenditures, free cash flow totaled -12.31M - equivalent to -0.02 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -12.31M |
| Free Cash Flow | -12.31M |
| FCF Per Share | -0.02 |
Margins
Jiangsu Yahong Meditech Co Ltd operates with a gross margin of 73.35, reflecting its pricing power and cost economics. The operating margin of -154.13 and net profit margin of -144.16 provide insight into operational efficiency.
| Gross Margin | 73.35 |
| Operating Margin | -154.13 |
| Pretax Margin | -148.28 |
| Profit Margin | -144.16 |
| EBITDA Margin | -154.13 |
Dividends & Yields
The company's payout ratio of -0.64 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.00 |
| Dividend Yield | N/A |
| Payout Ratio | -0.64 |
| Shareholder Yield | -0.80 |
| FCF Yield | 0.23 |
Scores
Jiangsu Yahong Meditech Co Ltd posts an Altman Z-Score of 7.58, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.58 |